Quick Answer
PROKIDNEY CORP. reported Cash And Cash Equivalents At Carrying Value of $108.54 million for the year ending 2025.
- PROKIDNEY CORP. showed an increase of +9.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from PROKIDNEY CORP.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $223.5 thousand | Q3 2021: $542.3 thousand | Q3 2022: $506.33 million | Q1 2023: $271.64 million | Q2 2023: $243.55 million | Q3 2023: $191.39 million | Q1 2024: $84.39 million | Q2 2024: $214.51 million | Q3 2024: $108.09 million | Q1 2025: $97.81 million | Q2 2025: $84.94 million | Q3 2025: $95.32 million.
- Over the full 5 years of available data (2021 to 2025), PROKIDNEY CORP.'s Cash And Cash Equivalents At Carrying Value has grown by 428.0%.
- Historical annual values: Fiscal year 2025: $108.54 million | Fiscal year 2024: $99.12 million | Fiscal year 2023: $60.65 million | Fiscal year 2022: $490.25 million | Fiscal year 2021: $20.56 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: